Main menu-eng



Professor Meng-Ru Shen



Project Name

Integrating clinical and genomic profiles to develop the therapeutic strategies for high risk colorectal cancer via big bio-data analytics


Project Intro

Colorectal cancer (CRC) is the most commonly diagnosed gastrointestinal cancer and the third most common cause of cancer-related death in the United States and Taiwan. However, recurrence is common and is seen in nearly 30% of stage III colorectal cancer patients receiving adjuvant chemotherapy after 5 years. Current clinic-pathologic information is inadequate for prediction of colon cancer recurrence, providing the therapeutic targets and biomarkers for monitor. To build up the genomics landscape of colorectal cancer stage III patients and identify the clinical use of genetic molecular markers to predict the risk of recurrence are needed.

    We have established a multiple- disciplinary research team, many experts from the college of engineering and computing engineering, biostatics, medicine to approach the cancer genomics. Comparing with the benchmark of The Cancer Genome Atlas (TCGA) cancer genomics datasets, we have established more comprehensive big biodata form a prospective clinical trial in CRC cancer patients. We also find the ethnic difference of genetic variants and publish article in high impact journal.

    In this study, we will develop artificial intelligence (AI) model and software for high risk cancer recurrence prediction, new treatment strategies and treatment monitor. We will conduct 3 subprojects for interpretation and discovery of biological insights and molecular mechanisms in recurrence risk prediction for CRC. The subprojects aim as followings: subproject1. development of genomic AI model and software for CRC risk prediction; subproject 2. identify the drug targets and find the new treatment strategies by using machine learning pipeline in CRC patients; subproject 3. update our big bio-data and develop predictive biomarkers

    In conclusion, this integrated AI genomic and mechanistic study provides insights into the disease biology and diagnostic classification of advanced colorectal cancer that could have a direct effect on treatment recommendations for patients, and provides opportunities for genome-guided clinical trials and drug development.



Project Host


Principal Investigator

 Meng-Ru Shen, Professor

Pharmacology Dept, NCKU


Co-Principal Investigator

 Pei-Fang Su, Associate Professor

Statistics Dept, NCKU


Chung-I Li , Assistant professor

Statistics Dept, NCKU


Peng-Chan Lin, Assistant Professor

Internal Medicine Dept, NCKU


Yu-Min Yeh, Attending Physician

Internal Medicine Dept, NCKU Hospital



 Website To Link

PI website


Host's Public Contact Method


E-mail:This email address is being protected from spambots. You need JavaScript enabled to view it.



  Representative Pictures Of The Research



Figure1. We integrate clinical and genomic profiles to develop the therapeutic strategies for high risk cancer patients via big bio-data analytics. Multidisciplinary research teams including computing engineering, biostatics and medicine join our studies of cancer genomics by integrating clinical and genomic profiles. The ultimate aim is to highlight the survival-associated molecular pathways of advanced cancer which will provide insights into the ethnic difference of disease biology and impact on treatment recommendations and genome-guided clinical trials of advanced cancer.



Figure2. A “holistic” approach in these 3 projects.





70101 台南市東區大學路1號 成功校區 資訊工程系 舊館1樓4220辦公室
No.4220, CSIE Dept (old building), No.1, University Road, Tainan City 701, Taiwan (R.O.C)

內容 版權所有© 2018 AIBMRC   網頁設計:陳彥伶 陳怡君